HUE068790T2 - Javított szérumalbumin kötõanyagok - Google Patents
Javított szérumalbumin kötõanyagokInfo
- Publication number
- HUE068790T2 HUE068790T2 HUE18707848A HUE18707848A HUE068790T2 HU E068790 T2 HUE068790 T2 HU E068790T2 HU E18707848 A HUE18707848 A HU E18707848A HU E18707848 A HUE18707848 A HU E18707848A HU E068790 T2 HUE068790 T2 HU E068790T2
- Authority
- HU
- Hungary
- Prior art keywords
- serum albumin
- improved serum
- albumin binders
- binders
- improved
- Prior art date
Links
- 102000007562 Serum Albumin Human genes 0.000 title 1
- 108010071390 Serum Albumin Proteins 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762446988P | 2017-01-17 | 2017-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE068790T2 true HUE068790T2 (hu) | 2025-01-28 |
Family
ID=61521465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18707848A HUE068790T2 (hu) | 2017-01-17 | 2018-01-17 | Javított szérumalbumin kötõanyagok |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11414481B2 (enExample) |
| EP (3) | EP3571225B1 (enExample) |
| JP (3) | JP7219220B2 (enExample) |
| KR (2) | KR20240013861A (enExample) |
| CN (2) | CN110191896B (enExample) |
| AU (2) | AU2018209151B2 (enExample) |
| BR (1) | BR112019014599A2 (enExample) |
| CA (1) | CA3050575A1 (enExample) |
| DK (1) | DK3571225T3 (enExample) |
| ES (1) | ES2991459T3 (enExample) |
| FI (1) | FI3571225T3 (enExample) |
| HR (1) | HRP20241469T1 (enExample) |
| HU (1) | HUE068790T2 (enExample) |
| IL (2) | IL267894B2 (enExample) |
| LT (1) | LT3571225T (enExample) |
| MX (2) | MX2019008496A (enExample) |
| PT (1) | PT3571225T (enExample) |
| RS (1) | RS66117B1 (enExample) |
| SG (2) | SG10202108972RA (enExample) |
| SI (1) | SI3571225T1 (enExample) |
| WO (1) | WO2018134235A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| CA2837998C (en) * | 2011-06-23 | 2022-03-01 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| KR20230061582A (ko) | 2016-12-07 | 2023-05-08 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 |
| RS66173B1 (sr) | 2017-01-17 | 2024-12-31 | Ablynx NV | Poboljšana veziva serumskog albumina |
| LT3571225T (lt) * | 2017-01-17 | 2024-11-11 | Ablynx Nv | Patobulintos serumo albumino rišamosios medžiagos |
| CN114981300B (zh) | 2019-12-06 | 2025-10-31 | 艾伯霖克斯公司 | 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽 |
| JP7719775B2 (ja) | 2019-12-06 | 2025-08-06 | アブリンクス エン．ヴェー． | ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
| JP7641968B2 (ja) | 2019-12-09 | 2025-03-07 | アブリンクス エン．ヴェー． | Ｉｌ－１３およびｔｓｌｐを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
| WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
| IL296767A (en) | 2020-03-30 | 2022-11-01 | Ablynx Nv | Method for the production and purification of multivalent immunoglobulin single variable domains |
| WO2022063984A1 (en) | 2020-09-25 | 2022-03-31 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| CA3205422A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| US20240092919A1 (en) | 2020-12-18 | 2024-03-21 | Ablynx N. V. | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| EP4263602A1 (en) | 2020-12-18 | 2023-10-25 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
| AU2022409733A1 (en) | 2021-12-17 | 2024-08-01 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
| IL317588A (en) | 2022-06-14 | 2025-02-01 | Ablynx Nv | Single immunoglobulin variable sites targeting the T cell receptor |
| CN120077065A (zh) | 2022-07-27 | 2025-05-30 | 阿布林克斯有限公司 | 与新生儿Fc受体的特定表位结合的多肽 |
| WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
| WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
| WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| CN121263437A (zh) | 2023-03-14 | 2026-01-02 | 奥德赛治疗股份有限公司 | 抗cd25抗原结合蛋白及其用途 |
| TW202448951A (zh) | 2023-05-17 | 2024-12-16 | 美商奧迪希治療公司 | 經修飾之單域抗體 |
| KR102822958B1 (ko) * | 2023-05-23 | 2025-06-20 | 대한민국(해양경찰청 해양경찰연구센터장) | 고래 불법포획 감식용 신속진단키트 |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| WO2025006846A2 (en) | 2023-06-29 | 2025-01-02 | Odyssey Therapeutics, Inc. | Anti-trailr2 antigen-binding proteins and uses thereof |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| AR133725A1 (es) | 2023-09-04 | 2025-10-29 | Sanofi Sa | Polipéptidos para uso en el tratamiento de tumores que expresan glipicano-3 |
| AR133903A1 (es) | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
| WO2025080751A2 (en) | 2023-10-13 | 2025-04-17 | Odyssey Therapeutics, Inc. | Anti-cdh17 antigen-binding proteins and uses thereof |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| TW202540188A (zh) | 2023-12-01 | 2025-10-16 | 比利時商艾伯霖克斯公司 | 精準活化的多肽 |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| US20250236673A1 (en) | 2023-12-22 | 2025-07-24 | Ablynx N.V. | Protein-based carriers for site-specific amine conjugation |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025217579A1 (en) * | 2024-04-12 | 2025-10-16 | Paragon Therapeutics, Inc. | Anti-hsa vhh antibodies and compositions thereof |
| US12459994B2 (en) | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| WO2025255558A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof |
| WO2025255435A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Antigen-binding proteins against serum albumin and uses thereof |
| WO2026006708A2 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| US6742038B2 (en) | 2000-04-07 | 2004-05-25 | Danger, Inc. | System and method of linking user identification to a subscriber identification module |
| WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP2284192A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| JP2008521870A (ja) | 2004-12-02 | 2008-06-26 | ドマンティス リミテッド | 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用 |
| EP3613767A1 (en) | 2005-05-18 | 2020-02-26 | Ablynx N.V. | Improved nanobodiestm against tumor cecrosis factor-alpha |
| EP3415535B1 (en) | 2005-05-20 | 2020-12-09 | Ablynx N.V. | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
| US20080311111A1 (en) | 2005-12-01 | 2008-12-18 | Drew Philip D | Competitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1 |
| JP2009519011A (ja) | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| EP1976991A1 (en) | 2006-01-24 | 2008-10-08 | Domantis Limited | Fusion proteins that contain natural junctions |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CA2663042A1 (en) * | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| AU2009248049B2 (en) | 2008-05-16 | 2015-07-23 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| CN102574914A (zh) | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | 改进的抗血清清蛋白结合性单可变区 |
| CA2774552A1 (en) | 2009-09-30 | 2011-04-07 | Glaxo Group Limited | Drug fusions and conjugates with extended half life |
| WO2012020143A1 (en) | 2010-08-13 | 2012-02-16 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| AU2011290797A1 (en) | 2010-08-20 | 2013-04-11 | Glaxosmithkline Intellectual Property Development Limited | Improved anti-serum albumin binding variants |
| US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| CA2837998C (en) * | 2011-06-23 | 2022-03-01 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2944653A1 (en) * | 2011-06-23 | 2015-11-18 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| US20150344568A1 (en) * | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| US9573992B2 (en) | 2011-06-23 | 2017-02-21 | Ablynx N.V. | Serum albumin binding proteins |
| WO2012174741A1 (en) | 2011-06-24 | 2012-12-27 | Google Inc. | Determining cross-language query suggestion based on query translations |
| ES2813432T3 (es) | 2011-08-17 | 2021-03-23 | Glaxo Group Ltd | Proteínas y péptidos modificados |
| US20130129727A1 (en) | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| WO2014037419A1 (en) | 2012-09-04 | 2014-03-13 | Vib Vzw | Immunoglobulin single variable domains directed against cd74 and uses derived thereof |
| US20140186365A1 (en) * | 2013-01-03 | 2014-07-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| KR20230145503A (ko) | 2014-05-16 | 2023-10-17 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| WO2016118733A1 (en) | 2015-01-21 | 2016-07-28 | Inhibrx Biopharma LLC | Non-immunogenic single domain antibodies |
| SI3294768T1 (sl) | 2015-05-13 | 2019-11-29 | Ablynx Nv | Polipeptidi, ki rekrutirajo celice T, na osnovi reaktivnosti TCR alfa/beta |
| SI3374392T1 (sl) * | 2015-11-13 | 2022-04-29 | Ablynx Nv | Izboljšane variabilne domene imunoglobulina, ki vežejo serumski albumin |
| AU2016360987A1 (en) | 2015-11-27 | 2018-06-07 | Ablynx Nv | Polypeptides inhibiting CD40L |
| KR20230061582A (ko) | 2016-12-07 | 2023-05-08 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 |
| RS66173B1 (sr) * | 2017-01-17 | 2024-12-31 | Ablynx NV | Poboljšana veziva serumskog albumina |
| LT3571225T (lt) * | 2017-01-17 | 2024-11-11 | Ablynx Nv | Patobulintos serumo albumino rišamosios medžiagos |
| AR133903A1 (es) * | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
-
2018
- 2018-01-17 LT LTEPPCT/EP2018/051083T patent/LT3571225T/lt unknown
- 2018-01-17 SG SG10202108972RA patent/SG10202108972RA/en unknown
- 2018-01-17 IL IL267894A patent/IL267894B2/en unknown
- 2018-01-17 KR KR1020247002265A patent/KR20240013861A/ko not_active Ceased
- 2018-01-17 EP EP18707848.0A patent/EP3571225B1/en active Active
- 2018-01-17 HR HRP20241469TT patent/HRP20241469T1/hr unknown
- 2018-01-17 WO PCT/EP2018/051083 patent/WO2018134235A1/en not_active Ceased
- 2018-01-17 ES ES18707848T patent/ES2991459T3/es active Active
- 2018-01-17 SI SI201831169T patent/SI3571225T1/sl unknown
- 2018-01-17 IL IL312292A patent/IL312292A/en unknown
- 2018-01-17 PT PT187078480T patent/PT3571225T/pt unknown
- 2018-01-17 CN CN201880007313.6A patent/CN110191896B/zh active Active
- 2018-01-17 BR BR112019014599-0A patent/BR112019014599A2/pt unknown
- 2018-01-17 CN CN202311123454.3A patent/CN117285623A/zh active Pending
- 2018-01-17 DK DK18707848.0T patent/DK3571225T3/da active
- 2018-01-17 CA CA3050575A patent/CA3050575A1/en active Pending
- 2018-01-17 SG SG11201906264YA patent/SG11201906264YA/en unknown
- 2018-01-17 KR KR1020197024113A patent/KR102662499B1/ko active Active
- 2018-01-17 AU AU2018209151A patent/AU2018209151B2/en active Active
- 2018-01-17 FI FIEP18707848.0T patent/FI3571225T3/fi active
- 2018-01-17 MX MX2019008496A patent/MX2019008496A/es unknown
- 2018-01-17 RS RS20241215A patent/RS66117B1/sr unknown
- 2018-01-17 JP JP2019538382A patent/JP7219220B2/ja active Active
- 2018-01-17 HU HUE18707848A patent/HUE068790T2/hu unknown
- 2018-01-17 EP EP24191388.8A patent/EP4442707A3/en active Pending
- 2018-01-17 US US16/477,918 patent/US11414481B2/en active Active
- 2018-01-17 EP EP24191393.8A patent/EP4442709A3/en active Pending
-
2019
- 2019-07-16 MX MX2023005374A patent/MX2023005374A/es unknown
-
2022
- 2022-06-29 US US17/852,604 patent/US20230060574A1/en active Pending
- 2022-12-08 JP JP2022196232A patent/JP7628996B2/ja active Active
-
2024
- 2024-11-22 JP JP2024204085A patent/JP2025026992A/ja active Pending
-
2025
- 2025-05-13 AU AU2025203430A patent/AU2025203430A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267894A (en) | Improved serum albumin binding agents | |
| IL267897A (en) | Improved serum albumin binding agents | |
| ZA201804317B (en) | Altered april binding antibodies | |
| PT3583125T (pt) | Proteínas de fusão ao domínio de ligação à albumina | |
| ZA201804601B (en) | Psma binding antibody and uses thereof | |
| HUE064772T2 (hu) | Kötõanyag rendszer | |
| PL3246370T3 (pl) | Bezpośrednio przylegający, przezroczysty, zgrzewany wiążący środek do powlekania i zamykania przezroczystych folii z tworzywa sztucznego | |
| ZA201901862B (en) | Modified factor h binding protein | |
| LT3452515T (lt) | Her-2 surišantys antikūnai | |
| GB201610063D0 (en) | Binders | |
| ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
| GB201615588D0 (en) | TSLP Binding Proteins | |
| IL267318A (en) | link test | |
| GB201614627D0 (en) | Antigen binding proteins | |
| HK1261097A1 (en) | Improved serum albumin binders | |
| GB201715149D0 (en) | IL-ß binding antibody | |
| GB201802995D0 (en) | File serving | |
| IL256197A (en) | Binding folder | |
| ZA201707980B (en) | Binding folder | |
| PH32016001013S1 (en) | Clip binder |